Genmab — Februar 2021

JørgenVarnæs

Dengang var der ingen CR’er

henrik48

Jeg tror jeg vil foretage et lille støtteopkøb...:-)

E_L

-- TEPEZZA (teprotumumab-trbw) Fourth-Quarter 2020 Net Sales of $343.7 Million; Full-Year 2020 Net Sales of $820.0 Million, Significantly Exceeding Launch-Year Expectations; Driving One of the Best Rare Disease Medicine Launches in History --

E_L

https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-record-fourth-quarter-and-full

E_L

The Company expects TEPEZZA full-year 2021 net sales of greater than $1.275 billion

JørgenVarnæs

Nice number

GeorgeBest

Guggenheim sænker Genmabs målkurs til 2648 fra 2782

Darvin

Fortsat et pænt mål! Har smidt en opdateret liste med Kursmål i debatten, incl. Guggenheim En ting er at analytikerne har kigget på tallene, men det fremgår klart at de netop kun har tænkt efter. Genmab er en aktie man skal eje, men investering koster på den korte bane https://www.proinvestor.com/boards/89730#postdiv91346

Solsen

I assume no sales of Tepezza Q121.

E_L

So, $812m @ FX rate 6.12 = dkk 5.018m. Royalties were dkk298m as per annual report =5.94%. So we can assume 6% flat given some rounding and the fx rate used.

E_L

So for 2021 they project 1275m * 6.12 = dkk7803m sales, @ 6% royalty is dkk468m

Solsen

Yes thats true. And 460 mln dkk to Genmab. Only 140 mln left for Kesimpta.

Solsen

I used 6 dkk pr doller

E_L

even better, i should have too, that is what Genmab used for 2021

Solsen

Genmab will easily get 600 mln dkk from those two assets.

E_L

Yes , agree, Pagano is clearly low-balling this range of DKK400 million to DKK600 million relates to TEPEZZA and Kesimpta.

kkjoel

They call them "conservative accounting principles"

Bulder

Aren't they low-balling the most?

kkjoel

And nicely calculated btw. Have corrected the number in the Wiki article.

E_L

yes, i feel they are, and that is fine, i am conservative too, but it is best to calculate ourselves to make sure that it is indeed conservative